胆汁淤积性肝病的正确认识与科学管理

doi:10.3969/j.issn.1672-5069.2019.05.036

Abstract

Lu Lungen. Cholestatic liver diseases：What we know and how to deal with[J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.

[1] Kuntz K,Kuntz HD.Cholestasi. Hepatology:principles and practice. 2nd ed. Springer Medizin Verlag Heidelberg,2006:227-242.
[2] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[3] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of cholestatic liver diseases. J Hepatol,2009,51:237-267.
[4] Beuers U,Kremer AE,Bolier R,et al.Pruritus in cholestasis: facts and fiction. Hepatology,2014,60:399-407.
[5] Lu LG .Current situation in basic and clinical research on cholestatic liver diseases. 中华肝脏病杂志,2008,16:561-563.
[6] Jungst C,Lammert F.Cholestatic liver disease. Dig Dis,2013,31:152-154.
[7] Paumgartner G,Beuers U.Ursodeoxycholic acid in cholestatic liver disease:mechanisms of action and therapeutic use revisited. Hepatology,2002,36:525-531.
[8] Lindor KD,Kowdley KV,Luketic V a C,et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology,2009,50(3): 808-814.
[9] Lu SC,Mato JM.S-adenosylmethionine in liver health,injury,and cancer. Physiol Rev,2012,92(4):1515-1542.
[10] Carrion AF,Rosen JD,Levy C.Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis,2018,22(3):517-532.
[11] Panebianco C,Oben J A,Vinciguerra M,et al.Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal:a putative synergy between retinoic acid and PPAR-gamma signalings. Clin Exp Med,2017,17(3):269-280.
[12] Assis D N,Abdelghany O,Cai SY,et al.Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis:A human pilot study. J Clin Gastroenterol,2017,51(2):e11-e16.
[13] Wahlström A,Kovatcheva-Datchary P,Stöhlman M,et al. Crosstalk between bile acids and gut microbiota and tts impact on Farnesoid X receptor signalling. Dig Dis,2017,35(3):246-250.
[14] Kowdley K V,Luketic V,Chapman R,et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology,2018,67(5):1890-1902.
[15] De Vries E,Beuers U.Management of cholestatic disease in 2017. Liver Int,2017,37(S1):123-129.
[16] Reig A,Sesé P,Parés A.Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol,2018,113(1): 49-55.
[17] Santiago P,Scheinberg A R,Levy C.Cholestatic liver diseases:new targets,new therapies. Therap Adv Gastroenterol,2018,11:1756284818787400-1756284818787400.
[18] Tabibian J H,Weeding E,Jorgensen R A,et al.Randomised clinical trial:vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther,2013,37(6):604-612.
[19] Fickert P,Hirschfield G M,Denk G,et al.Nor ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol,2017,67(3):549-558.
[20] Li W,Qin H,Hua C,et al.Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev,2014,23(20):2482-2489.

Cholestatic liver diseases：What we know and how to deal with

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[5]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[8]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[9]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[10]	Li Qi, Zeng Ajuan, Meng Wen, et al.. Clinical analysis of cholecystopathy in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2019, 22(6): 924-927.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.